|
Subgroup
|
No. of studies
|
RR(95% CI)
|
I2 value (%)
|
P value
|
|---|
|
All studies
|
12
|
1.25 (1.14,1.37)
|
37.8
|
0.022
|
|
Type of NMSC
| | | | |
|
Squamous cell skin cancer
|
4
|
1.34 (1.10,1.63)
|
44.2
|
0.096
|
|
Basal cell skin cancer
|
3
|
1.16 (1.02,1.32)
|
0.0
|
0.893
|
|
Type of biologic therapy
|
|
TNFI
|
10
|
1.23 (1.10,1.37)
|
45.2
|
0.017
|
|
Abatacept
|
3
|
2.00 (1.27,3.15)
|
0.0
|
0.689
|
|
Rituximab
|
2
|
1.02 (0.67,1.56)
|
0.0
|
0.754
|
|
Treatment years
|
|
Less than 2 years
|
2
|
1.04 (0.79,1.37)
|
0.0
|
0.633
|
|
More than 2 years
|
6
|
1.26 (1.17,1.37)
|
19.9
|
0.248
|
|
Study quality
|
|
NOS score = 7
|
3
|
1.16 (1.00,1.35)
|
0.4
|
0.426
|
|
NOS score = 8
|
9
|
1.29 (1.15,1.44)
|
42.8
|
0.028
|
|
Sample size
|
|
< 10,000
|
12
|
1.26 (1.12,1.42)
|
45.0
|
0.009
|
|
≥ 10,000
|
4
|
1.21 (1.07,1.36)
|
0.0
|
0.667
|
- NMSC: non-melanoma skin cancer; TNFIs: tumor necrosis factor inhibitors; NOS: Newcastle–Ottawa Quality Assessment Scale; RR: relative risk; CI: confidence interval
